All In Biotech

Drug Trial Radar · NCT04882085

Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults

AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED STUDY TO ESTIMATE THE EFFICACY AND SAFETY OF CEFTAZIDIME-AVIBACTAM (CAZ-AVI) VERSUS BEST AVAILABLE TREATMENT (BAT) IN THE TREATMENT OF INFECTIONS DUE TO CARBAPENEM-RESISTANT GRAM-NEGATIVE PATHOGENS IN CHINESE ADULTS

Last checked: Nov 20, 2026Latest source record: Oct 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

60

Actual

Start

Aug 26, 2021

Primary completion

Aug 31, 2023

Study completion Aug 31, 2023

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
May 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, randomized, multi-center, interventional, active-controlled Phase 4 study to evaluate the efficacy and safety of CAZ-AVI versus BAT in the treatment of infected participants with selected infection types (Hospital Acquired Pneumonia \[HAP\] (including Ventilator-Associated Pneumonia \[VAP\]); Complicated Urinary-Tract Infection \[cUTI\]; Complicated Intra-Abdominal Infection \[cIAI\]; Bloodstream Infection \[BSI\]) due to carbapenem-resistant Gram-negative pathogens in China.This study will be an estimation study. The statistical inference will be based on point estimate and confidence interval.

Conditions

  • Urinary Tract Infection
  • Acute Pyelonephritis
  • Hospital Acquired Pneumonia
  • Ventilator-associated Pneumonia
  • Bacteremia
  • Intra-abdominal Infection

Interventions

  • Zavicefta, Ceftazidime-AvibactamDrug

    CAZ-AVI 2.5 g (2 g ceftazidime + 0.5 g avibactam) administered IV as a 2 hour infusion every 8 hours. Dose adjustments are available for participants with CrCL ≤50 mL/min.

  • Best Available TreatmentDrug

    main treatment expected to be used as either monotherapy or in combination are colistin, tigecycline, fosfomycin, amikacin, and meropenem

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Clinical Cure at Test of Cure (TOC) Visit - Microbiologically Modified Intent-to-Treat (mMITT) Analysis SetTime frame: At TOC visit (From Day 21 up to Day 24)

Locations

37 sites in 1 country. Site status is shown where the registry gives one.

  • Jiangyin People's Hospital

    Jiangyin, China

  • Shanghai Fifth People's Hospital, Fudan University

    Shanghai, China

  • The First Affiliated Hospital of Bengbu Medical

    Bengbu, Anhui, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • Chizhou People's Hospital

    Chizhou, Anhui, China

  • Fuyang People's Hospital

    Fuyang, Anhui, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Zhongshan Hospital Xiamen University

    Xiamen, Fujian, China

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, China

  • Qingyuan People's Hospital

    Qingyuan, Guangdong, China

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, China

  • The Second People's Hospital of Shenzhen

    Shenzhen, Guangdong, China

  • Affiliated Hospital of Guangdong Medical University

    Zhanjiang, Guangdong, China

  • Affiliated Hospital of Guilin Medical College

    Guilin, Guangxi, China

  • Affiliated Hospital of Zunyi Medical University

    Zunyi, Guizhou, China

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China

  • Luoyang Central Hospital

    Luoyang, Henan, China

  • NanYang central hospital

    Nanyang, Henan, China

  • Henan provincial people's hospital

    Zhengzhou, Henan, China

  • Henan provincial people's hospital

    Zhengzhou, Henan, China

  • Baotou Central Hospital

    Baotou, Inner Mongolia, China

  • Jiangyin People's Hospital

    Jiangyin, Jiangsu, China

  • Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • Subei People's Hospital of Jiangsu province

    Yangzhou, Jiangsu, China

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, China

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

  • Chengdu Xinhua Hospital

    Chengdu, Sichuan, China

  • Tianjin Chest Hospital

    Tianjin, Tianjin Municipality, China

  • The First People's Hospital of Kunming (South Hospital)

    Kunming, Yunnan, China

  • The First people's Hospital of Kunming

    Kunming, Yunnan, China

  • The First People's Hospital of Kunming Ganmei Hospital (North Hospital)

    Kunming, Yunnan, China

  • Zhejiang Hospital

    Hangzhou, Zhejiang, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China

  • Lishui People's Hospital

    Lishui, Zhejiang, China

  • Taizhou Hospital of Zhejiang Province

    Taizhou, Zhejiang, China

  • The 2nd Affiliated Hospital of WMU

    Wenzhou, Zhejiang, China

  • Wenzhou Central Hospital

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.